ABSTRACT
Fumarase (FH) deficiency is a rare autosomal recessive disease of the Krebs cycle causing severe neurological impairment in early childhood, characterized by encephalopathy with seizures and muscular hypotonia. Only a handful of patients with various recessive mutations in the FH gene have been described so far. Interestingly, autosomal dominant mutations in the same gene are associated with hereditary leiomyomatosis and renal cell cancer (HLRCC). We investigated a boy with developmental and growth delay, microcephaly, and muscular hypotonia recognized at the age of 3 months. No leiomyomatosis or renal cancer is known in the parents. Investigation of the patient's urine revealed massive fumarate excretion. FH activity was severely reduced in muscle and fibroblasts. Respirometric investigation of fibroblasts showed only modest changes indicating that fumarate mediated inhibition of enzymatic pathways other than oxidative phosphorylation might be more relevant in pathophysiology of FH deficiency. Molecular analysis revealed a known 435insK mutation on the paternal allele and a novel H275L mutation due to an A to T transversion of nucleotide 824 on the maternal allele. This mutation affects the same codon as a C to T transition of nucleotide 823, resulting in a H275Y mutation that was found in two families with HLRCC.
Subject(s)
Fumarate Hydratase/deficiency , Fumarate Hydratase/genetics , Metabolism, Inborn Errors/genetics , Metabolism, Inborn Errors/metabolism , Amino Acid Substitution , Cell Respiration , Child, Preschool , Fatal Outcome , Fumarate Hydratase/chemistry , Fumarate Hydratase/metabolism , Fumarates/urine , Heterozygote , Humans , Infant , Infant, Newborn , Lysine , Male , Mitochondria/enzymology , Mitochondria/metabolism , Models, Molecular , Muscle Hypotonia , Muscle, Skeletal/enzymology , Mutation , Psychomotor Disorders/genetics , Psychomotor Disorders/metabolismSubject(s)
Graft Rejection/therapy , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/immunology , Muromonab-CD3/therapeutic use , Pancreas Transplantation/immunology , Adult , California , Costs and Cost Analysis , Female , Graft Rejection/economics , Humans , Immunosuppressive Agents/economics , Male , Middle Aged , Muromonab-CD3/economics , Postoperative Complications , Remission Induction , Retrospective StudiesABSTRACT
BACKGROUND: The attack rate of cytomegalovirus (CMV) is over 50% in solid organ transplant recipients at risk for primary CMV infection and in those receiving antilymphocyte antibody therapy. Various CMV prophylaxis regimens over the last few years have reduced the attack rate to around 20% overall. METHODS: We report our results using high-dose acyclovir for 3 months after transplant, with targeted intravenous ganciclovir for the duration of any antilymphocyte antibody therapy, in our kidney and simultaneous pancreas/kidney transplant recipients. Records of 109 consecutive patients over a 2-year period were reviewed. RESULTS: Six cases of CMV disease were identified. Five cases occurred in 21 patients at risk for primary CMV disease (24%), whereas only one case occurred in 73 patients at risk for CMV reactivation (1.4%). CONCLUSION: We conclude that high-dose acyclovir and targeted ganciclovir is excellent prophylaxis against CMV reactivation in kidney and simultaneous pancreas/kidney transplantation.